Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Table 5 Costs, incremental costs and cost-effectiveness ratios* for ranibizumab treatment compared with no ranibizumab treatment for a 67-year old woman over the 2-year time horizon of MARINA†

	Cost			Cost per case of blindness prevented	Cost per blind-year prevented	Cost per QALY gained
	Ranibizumab treatment	No ranibizumab treatment	Difference
	$	$	$	$	$	$
Including caregiver costs
Ranibizumab cost
Wholesale price	78,900	42,700	36,300	145,400	116,500	308,400
Bevacizumab price	34,000	42,700	-8,700	Dominant^‡	Dominant	Dominant
Excluding caregiver costs
Ranibizumab cost
Wholesale price	56,700	5,800	50,900	204,100	163,500	432,900
Bevacizumab price	11,700	5,800	6,000	23,800	19,000	50,400

*Costs are in 2004 U.S. dollars and were rounded. Costs, blind-years and QALYs were discounted at 3% per annum
† Rosenfeld et al.[2]
‡ Dominant: The ranibizumab treatment strategy was more effective and cost less than the no ranibizumab strategy

ISSN: 1478-7547